New combo tackles liver cancer when standard treatment stops working

NCT ID NCT07192185

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding FOLFOX chemotherapy to the existing immunotherapy drugs atezolizumab and bevacizumab can help patients with advanced liver cancer whose disease has worsened on first-line treatment. The study will enroll 30 adults with Barcelona Clinic Liver Cancer stage C. Researchers will measure how many patients' tumors shrink and how long they live overall.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FOLFOX chemotherapy (oxaliplatin, leucovorin, 5-fluorouracil) plus atezolizumab and bevacizumab
What this could lead to: If successful, this could offer a new second-line treatment option for advanced liver cancer patients who have stopped responding to standard first-line therapy.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply broadly. Adding chemotherapy to immunotherapy also increases the risk of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.